Worldwide application and valuation of extracorporeal membrane oxygenation support during the COVID-19 pandemic (WAVES).

IF 1.1 4区 医学 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS Perfusion-Uk Pub Date : 2024-07-24 DOI:10.1177/02676591241267228
Akram M Zaaqoq, Silver Heinsar, Hwan-Jin Yoon, Nicole White, Matthew J Griffee, Jacky Y Suen, Gianluigi L Bassi, Jonathon P Fanning, Ahmad Labib Shehatta, Peta M A Alexander, Jeffrey P Jacobs, Heidi J Dalton, Roberto Lorusso, Sung-Min Cho, Giles J Peek, John F Fraser
{"title":"Worldwide application and valuation of extracorporeal membrane oxygenation support during the COVID-19 pandemic (WAVES).","authors":"Akram M Zaaqoq, Silver Heinsar, Hwan-Jin Yoon, Nicole White, Matthew J Griffee, Jacky Y Suen, Gianluigi L Bassi, Jonathon P Fanning, Ahmad Labib Shehatta, Peta M A Alexander, Jeffrey P Jacobs, Heidi J Dalton, Roberto Lorusso, Sung-Min Cho, Giles J Peek, John F Fraser","doi":"10.1177/02676591241267228","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The outcomes of COVID-19 patients on venovenous extracorporeal membrane oxygenation (VV-ECMO) varied. We aim to investigate the variability concerning location and timeframe. We conducted a retrospective analysis of data from 351 institutions in 53 countries. The primary outcome was survival to hospital discharge or death up to 90 days from ECMO start. The associations between calendar time (month and year) of ECMO initiation and the primary outcome were examined by Cox regression modeling. Multivariable survival analyses were adjusted for the time of ECMO start, age, body mass index, APACHE II, SOFA, and the duration of mechanical ventilation before ECMO.</p><p><strong>Results: </strong>1060 adult COVID-19 patients enrolled in the COVID-19 Critical Care Consortium (COVID Critical) international registry and required VV-ECMO support. The study period is from January 2020 to December 2021. The median age was 51 years old, and 70% were male patients. Most patients were from Europe (39.3%) and North America (37.4%). The in-hospital mortality of the entire cohort was 47.12%. In North America and Europe, there was an increased probability of death from May 2020 through February 2021. Latin America showed a steady rate of survival until late in the study. South Asia, the Middle East, and Africa showed an increased chance of mortality around May 2020. In the Asian-Pacific region, after February 2021, there was an increased probability of death. The time of ECMO initiation and advanced patient age were associated with increased mortality.</p><p><strong>Conclusion: </strong>Variability in the outcomes of COVID-19 patients on VV-ECMO existed within different regions. This variability reflects the differences in resources, policies, patient selection, management, and possibly COVID-19 virus subtypes. Our findings might help guide global response in the future by early adoption of patient selection protocols, worldwide policies, and delivery of resources.</p>","PeriodicalId":49707,"journal":{"name":"Perfusion-Uk","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Perfusion-Uk","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/02676591241267228","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: The outcomes of COVID-19 patients on venovenous extracorporeal membrane oxygenation (VV-ECMO) varied. We aim to investigate the variability concerning location and timeframe. We conducted a retrospective analysis of data from 351 institutions in 53 countries. The primary outcome was survival to hospital discharge or death up to 90 days from ECMO start. The associations between calendar time (month and year) of ECMO initiation and the primary outcome were examined by Cox regression modeling. Multivariable survival analyses were adjusted for the time of ECMO start, age, body mass index, APACHE II, SOFA, and the duration of mechanical ventilation before ECMO.

Results: 1060 adult COVID-19 patients enrolled in the COVID-19 Critical Care Consortium (COVID Critical) international registry and required VV-ECMO support. The study period is from January 2020 to December 2021. The median age was 51 years old, and 70% were male patients. Most patients were from Europe (39.3%) and North America (37.4%). The in-hospital mortality of the entire cohort was 47.12%. In North America and Europe, there was an increased probability of death from May 2020 through February 2021. Latin America showed a steady rate of survival until late in the study. South Asia, the Middle East, and Africa showed an increased chance of mortality around May 2020. In the Asian-Pacific region, after February 2021, there was an increased probability of death. The time of ECMO initiation and advanced patient age were associated with increased mortality.

Conclusion: Variability in the outcomes of COVID-19 patients on VV-ECMO existed within different regions. This variability reflects the differences in resources, policies, patient selection, management, and possibly COVID-19 virus subtypes. Our findings might help guide global response in the future by early adoption of patient selection protocols, worldwide policies, and delivery of resources.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19 大流行期间体外膜氧合支持的全球应用和估值(WAVES)。
目的:COVID-19 患者接受静脉体外膜氧合(VV-ECMO)治疗的结果各不相同。我们旨在研究地点和时间框架方面的差异。我们对来自 53 个国家 351 家机构的数据进行了回顾性分析。主要结果是 ECMO 启动后 90 天内出院或死亡的存活率。我们通过 Cox 回归模型研究了 ECMO 启动的日历时间(月和年)与主要结果之间的关系。多变量生存分析对 ECMO 启动时间、年龄、体重指数、APACHE II、SOFA 和 ECMO 前机械通气持续时间进行了调整:1060名成年COVID-19患者加入了COVID-19重症监护联盟(COVID Critical)国际注册,并需要VV-ECMO支持。研究时间为 2020 年 1 月至 2021 年 12 月。中位年龄为 51 岁,70% 为男性患者。大多数患者来自欧洲(39.3%)和北美(37.4%)。整个组群的院内死亡率为 47.12%。在北美和欧洲,2020 年 5 月至 2021 年 2 月期间的死亡概率有所上升。拉丁美洲的存活率一直保持稳定,直到研究后期。南亚、中东和非洲在 2020 年 5 月左右死亡几率上升。在亚太地区,2021 年 2 月之后,死亡几率增加。启动 ECMO 的时间和患者高龄与死亡率增加有关:结论:COVID-19 患者接受 VV-ECMO 治疗的结果在不同地区存在差异。这种差异反映了资源、政策、患者选择、管理以及 COVID-19 病毒亚型的不同。我们的研究结果可能有助于指导未来的全球应对措施,即尽早采用患者选择方案、全球政策和资源交付。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Perfusion-Uk
Perfusion-Uk 医学-外周血管病
CiteScore
3.00
自引率
8.30%
发文量
203
审稿时长
6-12 weeks
期刊介绍: Perfusion is an ISI-ranked, peer-reviewed scholarly journal, which provides current information on all aspects of perfusion, oxygenation and biocompatibility and their use in modern cardiac surgery. The journal is at the forefront of international research and development and presents an appropriately multidisciplinary approach to perfusion science.
期刊最新文献
Emergency laparotomy and endoscopic gastrostomy in patients on extra-corporeal membrane oxygenation (ECMO) support. The emerging role of minimally invasive extracorporeal circulation in totally endoscopic and robotic-assisted cardiac surgery procedures. Safety and feasibility of conversion from venoarterial to venovenous extracorporeal membrane oxygenation in pediatric patients: A case series. Successful management of pulmonary hemorrhage from lung carcinoid, in a patient on VenoArterial extracorporeal membrane oxygenation support. Learning: A lifelong process of evolution.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1